drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00405 | DB00486 | 128 | 1,614 | [
"DDInter517",
"DDInter1253"
] | Dexbrompheniramine | Nabilone | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Nabilone (marketed as Cesamet) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). Although structurally distinct from THC, nabilone mimics THC's structure and pharmacological activity through weak partial agonist activity at Cannabinoid-1 (CB1R) and... | Moderate | 1 | [
[
[
128,
24,
1614
]
],
[
[
128,
24,
530
],
[
530,
1,
1614
]
],
[
[
128,
63,
999
],
[
999,
24,
1614
]
],
[
[
128,
24,
94
],
[
94,
63,... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nabilone"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol (Compound) resembles Nabilone (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moder... |
DB01073 | DB08865 | 1,488 | 1,593 | [
"DDInter745",
"DDInter448"
] | Fludarabine | Crizotinib | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Moderate | 1 | [
[
[
1488,
24,
1593
]
],
[
[
1488,
6,
2104
],
[
2104,
57,
1593
]
],
[
[
1488,
21,
28771
],
[
28771,
60,
1593
]
],
[
[
1488,
24,
1060
],
[
1... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Fludarabine",
"{u} (Compound) binds {v} (Gene)",
"POLA1"
],
[
"POLA1",
"{u} (Gene) is downregulated by {v} (Com... | Fludarabine (Compound) binds POLA1 (Gene) and POLA1 (Gene) is downregulated by Crizotinib (Compound)
Fludarabine (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Crizotinib (Compound)
Fludarabine may cause a moderate interaction that could exacerbate diseases when t... |
DB00515 | DB11817 | 589 | 1,259 | [
"DDInter387",
"DDInter165"
] | Cisplatin | Baricitinib | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
589,
25,
1259
]
],
[
[
589,
63,
1461
],
[
1461,
23,
1259
]
],
[
[
589,
24,
949
],
[
949,
24,
1259
]
],
[
[
589,
24,
1129
],
[
1129,
... | [
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid ... |
DB05676 | DB06636 | 1,513 | 1,623 | [
"DDInter111",
"DDInter980"
] | Apremilast | Isavuconazonium | Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July... | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
1513,
24,
1623
]
],
[
[
1513,
24,
214
],
[
214,
63,
1623
]
],
[
[
1513,
63,
1101
],
[
1101,
24,
1623
]
],
[
[
1513,
25,
913
],
[
913,
... | [
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
... | Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene a... |
DB00539 | DB01169 | 11 | 57 | [
"DDInter1837",
"DDInter120"
] | Toremifene | Arsenic trioxide | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
11,
25,
57
]
],
[
[
11,
6,
8374
],
[
8374,
45,
57
]
],
[
[
11,
23,
1247
],
[
1247,
23,
57
]
],
[
[
11,
24,
603
],
[
603,
63,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"A... | Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Arsenic trioxide (Compound)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Arsenic trioxid... |
DB00388 | DB06655 | 1,636 | 5 | [
"DDInter1453",
"DDInter1077"
] | Phenylephrine | Liraglutide | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
1636,
24,
5
]
],
[
[
1636,
24,
1252
],
[
1252,
23,
5
]
],
[
[
1636,
63,
245
],
[
245,
24,
5
]
],
[
[
1636,
24,
480
],
[
480,
24,... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Liraglutide
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimep... |
DB00867 | DB06764 | 1,052 | 1,090 | [
"DDInter1606",
"DDInter1787"
] | Ritodrine | Tetryzoline (nasal) | Adrenergic beta-agonist used to control premature labor. | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Moderate | 1 | [
[
[
1052,
24,
1090
]
],
[
[
1052,
24,
144
],
[
144,
63,
1090
]
],
[
[
1052,
24,
688
],
[
688,
24,
1090
]
],
[
[
1052,
35,
480
],
[
480,
... | [
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetryzoline"
]
],
[
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
... | Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Ritodrine ... |
DB00912 | DB04868 | 473 | 478 | [
"DDInter1581",
"DDInter1293"
] | Repaglinide | Nilotinib | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
473,
24,
478
]
],
[
[
473,
6,
8374
],
[
8374,
45,
478
]
],
[
[
473,
21,
28762
],
[
28762,
60,
478
]
],
[
[
473,
24,
466
],
[
466,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Repaglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Repaglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Repaglinide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nilotinib (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Dar... |
DB00531 | DB01125 | 450 | 279 | [
"DDInter456",
"DDInter98"
] | Cyclophosphamide | Anisindione | Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause steril... | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Moderate | 1 | [
[
[
450,
24,
279
]
],
[
[
450,
24,
913
],
[
913,
63,
279
]
],
[
[
450,
62,
268
],
[
268,
24,
279
]
],
[
[
450,
24,
328
],
[
328,
24,... | [
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
... | Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Peginter... |
DB00959 | DB01309 | 1,486 | 1,254 | [
"DDInter1191",
"DDInter933"
] | Methylprednisolone | Insulin glulisine | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
1486,
24,
1254
]
],
[
[
1486,
40,
167
],
[
167,
24,
1254
]
],
[
[
1486,
24,
1603
],
[
1603,
24,
1254
]
],
[
[
1486,
63,
1645
],
[
1645... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrocortisone"
],
[
"Hydrocortisone",... | Methylprednisolone (Compound) resembles Hydrocortisone (Compound) and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Captopril and Captopril may cause a mo... |
DB00059 | DB08907 | 1,560 | 1,344 | [
"DDInter1404",
"DDInter280"
] | Pegaspargase | Canagliflozin | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
1560,
24,
1344
]
],
[
[
1560,
24,
549
],
[
549,
1,
1344
]
],
[
[
1560,
24,
1486
],
[
1486,
24,
1344
]
],
[
[
1560,
63,
176
],
[
176,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a mo... |
DB09052 | DB11988 | 250 | 270 | [
"DDInter220",
"DDInter1321"
] | Blinatumomab | Ocrelizumab | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostl... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
250,
24,
270
]
],
[
[
250,
63,
134
],
[
134,
24,
270
]
],
[
[
250,
24,
287
],
[
287,
63,
270
]
],
[
[
250,
24,
748
],
[
748,
24,... | [
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
... | Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab
Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fuma... |
DB00683 | DB01234 | 1,382 | 1,220 | [
"DDInter1212",
"DDInter513"
] | Midazolam | Dexamethasone | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Minor | 0 | [
[
[
1382,
23,
1220
]
],
[
[
1382,
62,
1573
],
[
1573,
1,
1220
]
],
[
[
1382,
23,
1486
],
[
1486,
40,
1220
]
],
[
[
1382,
6,
21998
],
[
219... | [
[
[
"Midazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Midazolam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Prednisone"
],
[
... | Midazolam may cause a minor interaction that can limit clinical effects when taken with Prednisone and Prednisone (Compound) resembles Dexamethasone (Compound)
Midazolam may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone and Methylprednisolone (Compound) resembles Dexametha... |
DB00218 | DB00731 | 1,176 | 1,144 | [
"DDInter1247",
"DDInter1269"
] | Moxifloxacin | Nateglinide | Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment. | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Major | 2 | [
[
[
1176,
25,
1144
]
],
[
[
1176,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
1176,
25,
609
],
[
609,
63,
1144
]
],
[
[
1176,
25,
1424
],
[
14... | [
[
[
"Moxifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nateglinide"
]
],
[
[
"Moxifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v... | Moxifloxacin (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (Compound)
Moxifloxacin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Nategli... |
DB00447 | DB09268 | 1,457 | 1,662 | [
"DDInter1090",
"DDInter1464"
] | Loracarbef | Picosulfuric acid | Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
1457,
24,
1662
]
],
[
[
1457,
63,
597
],
[
597,
24,
1662
]
],
[
[
1457,
24,
1096
],
[
1096,
62,
1031
],
[
1031,
24,
1662
]
],
[
[
1457... | [
[
[
"Loracarbef",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Loracarbef",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
... | Loracarbef may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Loracarbef may cause a moderate interaction that could exacerbate diseases when taken with Myco... |
DB00539 | DB00640 | 11 | 1,585 | [
"DDInter1837",
"DDInter31"
] | Toremifene | Adenosine | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Major | 2 | [
[
[
11,
25,
1585
]
],
[
[
11,
18,
2183
],
[
2183,
57,
1585
]
],
[
[
11,
21,
28890
],
[
28890,
60,
1585
]
],
[
[
11,
25,
477
],
[
477,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Adenosine"
]
],
[
[
"Toremifene",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
... | Toremifene (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Adenosine (Compound)
Toremifene (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Adenosine (Compound)
Toremifene may lead to a major life threatening interaction when taken wit... |
DB00687 | DB11952 | 870 | 800 | [
"DDInter747",
"DDInter612"
] | Fludrocortisone | Duvelisib | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed tha... | Moderate | 1 | [
[
[
870,
24,
800
]
],
[
[
870,
63,
663
],
[
663,
24,
800
]
],
[
[
870,
24,
270
],
[
270,
63,
800
]
],
[
[
870,
24,
1683
],
[
1683,
2... | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duvelisib"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
... | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Duvelisib
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizu... |
DB11714 | DB14783 | 1,316 | 287 | [
"DDInter610",
"DDInter574"
] | Durvalumab | Diroximel fumarate | Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment. Produced by recombinant DNA technology in Chinese Hamster Ovary (CHO) cell suspension culture, durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody that works to promote... | Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting ... | Moderate | 1 | [
[
[
1316,
24,
287
]
],
[
[
1316,
63,
384
],
[
384,
24,
287
]
],
[
[
1316,
24,
270
],
[
270,
24,
287
]
],
[
[
1316,
64,
770
],
[
770,
... | [
[
[
"Durvalumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
]
],
[
[
"Durvalumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
... | Durvalumab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Durvalumab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab a... |
DB00373 | DB00757 | 461 | 1,166 | [
"DDInter1809",
"DDInter581"
] | Timolol | Dolasetron | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
461,
25,
1166
]
],
[
[
461,
24,
19
],
[
19,
40,
1166
]
],
[
[
461,
24,
85
],
[
85,
1,
1166
]
],
[
[
461,
6,
12523
],
[
12523,
45... | [
[
[
"Timolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"Hyoscyamine",
... | Timolol may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Dolasetron (Compound)
Timolol may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Dolasetron (Compound)
Timolol ... |
DB00405 | DB01142 | 128 | 1,264 | [
"DDInter517",
"DDInter593"
] | Dexbrompheniramine | Doxepin | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
128,
24,
1264
]
],
[
[
128,
24,
508
],
[
508,
24,
1264
]
],
[
[
128,
74,
1594
],
[
1594,
24,
1264
]
],
[
[
128,
40,
11439
],
[
11439,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Dexbrompheniramine (Compound) resembles Doxylamine (Compound) and Dexbrompheniramine may cause a moderate int... |
DB04868 | DB09034 | 478 | 1,313 | [
"DDInter1293",
"DDInter1733"
] | Nilotinib | Suvorexant | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
478,
24,
1313
]
],
[
[
478,
23,
1135
],
[
1135,
62,
1313
]
],
[
[
478,
64,
1213
],
[
1213,
24,
1313
]
],
[
[
478,
25,
1619
],
[
1619,
... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"... | Nilotinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Suvorexant
Nilotinib may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate... |
DB00798 | DB01333 | 1,132 | 207 | [
"DDInter815",
"DDInter328"
] | Gentamicin | Cefradine | Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963. It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negat... | A semi-synthetic cephalosporin antibiotic. | Moderate | 1 | [
[
[
1132,
24,
207
]
],
[
[
1132,
24,
315
],
[
315,
40,
207
]
],
[
[
1132,
63,
778
],
[
778,
1,
207
]
],
[
[
1132,
24,
1227
],
[
1227,
... | [
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefradine"
]
],
[
[
"Gentamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefprozil"
],
[
... | Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Cefprozil and Cefprozil (Compound) resembles Cefradine (Compound)
Gentamicin may cause a moderate interaction that could exacerbate diseases when taken with Cefixime and Cefixime (Compound) resembles Cefradine (Compound)
Gentamic... |
DB00927 | DB01403 | 1,559 | 9 | [
"DDInter712",
"DDInter1175"
] | Famotidine | Methotrimeprazine | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Moderate | 1 | [
[
[
1559,
24,
9
]
],
[
[
1559,
63,
1178
],
[
1178,
40,
9
]
],
[
[
1559,
63,
1164
],
[
1164,
1,
9
]
],
[
[
1559,
24,
401
],
[
401,
24... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrimeprazine"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
... | Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Methotrimeprazine (Compound)
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine (Compound) resembles M... |
DB00067 | DB00586 | 317 | 1,512 | [
"DDInter1921",
"DDInter537"
] | Vasopressin | Diclofenac | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Moderate | 1 | [
[
[
317,
24,
1512
]
],
[
[
317,
24,
1559
],
[
1559,
62,
1512
]
],
[
[
317,
24,
129
],
[
129,
63,
1512
]
],
[
[
317,
24,
1555
],
[
1555,
... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
... | Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a minor interaction that can limit clinical effects when taken with Diclofenac
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enza... |
DB06016 | DB11186 | 1,508 | 1,609 | [
"DDInter300",
"DDInter1427"
] | Cariprazine | Pentoxyverine | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
1508,
24,
1609
]
],
[
[
1508,
63,
104
],
[
104,
24,
1609
]
],
[
[
1508,
24,
849
],
[
849,
24,
1609
]
],
[
[
1508,
64,
1311
],
[
1311,
... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine a... |
DB00570 | DB11642 | 147 | 938 | [
"DDInter1936",
"DDInter1480"
] | Vinblastine | Pitolisant | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
147,
24,
938
]
],
[
[
147,
24,
112
],
[
112,
23,
938
]
],
[
[
147,
25,
760
],
[
760,
24,
938
]
],
[
[
147,
63,
600
],
[
600,
24,... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pitolisant
Vinblastine may lead to a major life threatening interaction when taken with Cobicistat and Cobicistat may ... |
DB00660 | DB04837 | 1,470 | 649 | [
"DDInter1163",
"DDInter407"
] | Metaxalone | Clofedanol | Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1470,
24,
649
]
],
[
[
1470,
24,
1376
],
[
1376,
24,
649
]
],
[
[
1470,
24,
832
],
[
832,
40,
649
]
],
[
[
1470,
63,
701
],
[
701,
... | [
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Tripelennam... |
DB00991 | DB01225 | 97 | 500 | [
"DDInter1358",
"DDInter645"
] | Oxaprozin | Enoxaparin | Oxaprozin is a non-narcotic, non-steroidal anti-inflammatory drug (NSAID), used to relieve the inflammation, swelling, stiffness, and joint pain associated with osteoarthritis and rheumatoid arthritis. | Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the inc... | Major | 2 | [
[
[
97,
25,
500
]
],
[
[
97,
21,
28804
],
[
28804,
60,
500
]
],
[
[
97,
24,
1039
],
[
1039,
24,
500
]
],
[
[
97,
63,
305
],
[
305,
2... | [
[
[
"Oxaprozin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
]
],
[
[
"Oxaprozin",
"{u} (Compound) causes {v} (Side Effect)",
"Purpura"
],
[
"Purpura",
"{u} (Side Effect) is caused by {v} (Compound)"... | Oxaprozin (Compound) causes Purpura (Side Effect) and Purpura (Side Effect) is caused by Enoxaparin (Compound)
Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eno... |
DB00673 | DB08912 | 723 | 1,040 | [
"DDInter112",
"DDInter462"
] | Aprepitant | Dabrafenib | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
723,
24,
1040
]
],
[
[
723,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
723,
54,
19196
],
[
19196,
15,
1040
]
],
[
[
723,
21,
28900
],
[
2890... | [
[
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Aprepitant",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Aprepitant (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Aprepitant (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class) and Cytochrome P450 3A4 Inducers (Pharmacologic Class) includes Dabrafenib (Compound)
Aprepitant (Compound) causes Abdominal pain (Side Ef... |
DB00209 | DB00572 | 352 | 85 | [
"DDInter1886",
"DDInter136"
] | Trospium | Atropine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosse... | Moderate | 1 | [
[
[
352,
24,
85
]
],
[
[
352,
24,
19
],
[
19,
24,
85
]
],
[
[
352,
35,
357
],
[
357,
24,
85
]
],
[
[
352,
40,
11389
],
[
11389,
40,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
"... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Atropine
Trospium (Compound) resembles Benzatropine (Compound) and Trospium may cause a moderate interaction that could exa... |
DB00054 | DB08901 | 1,432 | 1,468 | [
"DDInter6",
"DDInter1492"
] | Abciximab | Ponatinib | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Major | 2 | [
[
[
1432,
25,
1468
]
],
[
[
1432,
24,
1230
],
[
1230,
24,
1468
]
],
[
[
1432,
24,
41
],
[
41,
63,
1468
]
],
[
[
1432,
25,
4
],
[
4,
... | [
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
... | Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levo... |
DB00836 | DB00976 | 543 | 1,056 | [
"DDInter1088",
"DDInter1758"
] | Loperamide | Telithromycin | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Major | 2 | [
[
[
543,
25,
1056
]
],
[
[
543,
63,
1570
],
[
1570,
40,
1056
]
],
[
[
543,
6,
12523
],
[
12523,
45,
1056
]
],
[
[
543,
21,
28681
],
[
2868... | [
[
[
"Loperamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telithromycin"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
[
"Azith... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin (Compound) resembles Telithromycin (Compound)
Loperamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Telithromycin (Compound)
Loperamide (Compound) causes Hypersensitivity (Side Effe... |
DB00400 | DB00701 | 353 | 1,091 | [
"DDInter843",
"DDInter90"
] | Griseofulvin | Amprenavir | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Amprenavir is a protease inhibitor used to treat HIV infection. | Moderate | 1 | [
[
[
353,
24,
1091
]
],
[
[
353,
24,
34
],
[
34,
1,
1091
]
],
[
[
353,
6,
8374
],
[
8374,
45,
1091
]
],
[
[
353,
21,
28680
],
[
28680,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
],
... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir (Compound) resembles Amprenavir (Compound)
Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Amprenavir (Compound)
Griseofulvin (Compound) causes Rash (Side Effect) and Ra... |
DB00562 | DB00782 | 1,014 | 1,123 | [
"DDInter188",
"DDInter1535"
] | Benzthiazide | Propantheline | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Minor | 0 | [
[
[
1014,
23,
1123
]
],
[
[
1014,
1,
359
],
[
359,
62,
1123
]
],
[
[
1014,
40,
674
],
[
674,
62,
1123
]
],
[
[
1014,
1,
323
],
[
323,
... | [
[
[
"Benzthiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Propantheline"
]
],
[
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may ca... | Benzthiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a minor interaction that can limit clinical effects when taken with Propantheline
Benzthiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a minor interaction that can limit clinical effects ... |
DB00916 | DB01059 | 112 | 956 | [
"DDInter1202",
"DDInter1313"
] | Metronidazole | Norfloxacin | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Minor | 0 | [
[
[
112,
23,
956
]
],
[
[
112,
23,
872
],
[
872,
40,
956
]
],
[
[
112,
62,
1176
],
[
1176,
1,
956
]
],
[
[
112,
23,
1539
],
[
1539,
... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
]
],
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gemifloxacin"
],
... | Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Metronidazole may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin... |
DB00554 | DB00673 | 1,027 | 723 | [
"DDInter1478",
"DDInter112"
] | Piroxicam | Aprepitant | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
1027,
24,
723
]
],
[
[
1027,
6,
6017
],
[
6017,
45,
723
]
],
[
[
1027,
24,
222
],
[
222,
62,
723
]
],
[
[
1027,
25,
1618
],
[
1618,
... | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Piroxicam",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
... | Piroxicam (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Aprepitant (Compound)
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Piroxicam may lead t... |
DB00619 | DB11932 | 1,419 | 327 | [
"DDInter909",
"DDInter3"
] | Imatinib | Abametapir (topical) | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
1419,
24,
327
]
],
[
[
1419,
24,
124
],
[
124,
63,
327
]
],
[
[
1419,
63,
1601
],
[
1601,
24,
327
]
],
[
[
1419,
24,
613
],
[
613,
... | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Imatinib may cau... |
DB09389 | DB09564 | 517 | 1,296 | [
"DDInter1315",
"DDInter930"
] | Norgestrel | Insulin degludec | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
517,
24,
1296
]
],
[
[
517,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
517,
24,
1385
],
[
1385,
63,
1296
]
],
[
[
517,
64,
1040
],
[
1040,
... | [
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Norgestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
... | Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Norgestrel may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide a... |
DB08886 | DB08908 | 637 | 713 | [
"DDInter126",
"DDInter564"
] | Asparaginase Erwinia chrysanthemi | Dimethyl fumarate | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
637,
24,
713
]
],
[
[
637,
63,
4
],
[
4,
24,
713
]
],
[
[
637,
24,
384
],
[
384,
63,
713
]
],
[
[
637,
24,
350
],
[
350,
24,
... | [
[
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases whe... | Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Asparaginase Erwinia chrysanthemi may cause a modera... |
DB01124 | DB01155 | 1,411 | 872 | [
"DDInter1828",
"DDInter813"
] | Tolbutamide | Gemifloxacin | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Gemifloxacin is a quinolone antibacterial agent with a broad-spectrum activity that is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. It is available in oral formulations. Gemifloxacin acts by inhibiting DNA synthesis through the inhibition of both DNA gyrase... | Major | 2 | [
[
[
1411,
25,
872
]
],
[
[
1411,
64,
739
],
[
739,
1,
872
]
],
[
[
1411,
25,
945
],
[
945,
40,
872
]
],
[
[
1411,
25,
1539
],
[
1539,
... | [
[
[
"Tolbutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
]
],
[
[
"Tolbutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
... | Tolbutamide may lead to a major life threatening interaction when taken with Lomefloxacin and Lomefloxacin (Compound) resembles Gemifloxacin (Compound)
Tolbutamide may lead to a major life threatening interaction when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Gemifloxacin (Compound)
Tolbutamide may ... |
DB01246 | DB08864 | 820 | 786 | [
"DDInter45",
"DDInter1595"
] | Alimemazine | Rilpivirine | A phenothiazine derivative that is used as an antipruritic. | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
820,
24,
786
]
],
[
[
820,
6,
8374
],
[
8374,
45,
786
]
],
[
[
820,
21,
28698
],
[
28698,
60,
786
]
],
[
[
820,
62,
112
],
[
112,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Alimemazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Alimemazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Alimemazine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Rilpivirine (Compound)
Alimemazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and ... |
DB00863 | DB01226 | 1,194 | 1,319 | [
"DDInter1568",
"DDInter1235"
] | Ranitidine | Mivacurium | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818]... | Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. | Minor | 0 | [
[
[
1194,
23,
1319
]
],
[
[
1194,
23,
648
],
[
648,
1,
1319
]
],
[
[
1194,
21,
28921
],
[
28921,
60,
1319
]
],
[
[
1194,
63,
1031
],
[
103... | [
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mivacurium"
]
],
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxacurium"
],
[
... | Ranitidine may cause a minor interaction that can limit clinical effects when taken with Doxacurium and Doxacurium (Compound) resembles Mivacurium (Compound)
Ranitidine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Mivacurium (Compound)
Ranitidine may cause a moderate interaction th... |
DB00414 | DB00679 | 590 | 684 | [
"DDInter16",
"DDInter1796"
] | Acetohexamide | Thioridazine | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | Moderate | 1 | [
[
[
590,
24,
684
]
],
[
[
590,
24,
1237
],
[
1237,
40,
684
]
],
[
[
590,
24,
216
],
[
216,
1,
684
]
],
[
[
590,
24,
1283
],
[
1283,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thioridazine"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Thioridazine (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) resembles Th... |
DB00688 | DB00911 | 955 | 458 | [
"DDInter1251",
"DDInter1811"
] | Mycophenolate mofetil | Tinidazole | Mycophenolate mofetil, also known as MMF or CellCept, is a prodrug of mycophenolic acid, and classified as a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). This drug is an immunosuppressant combined with drugs such as [Cyclosporine] and corticosteroids to prevent organ rejection after hepatic, ren... | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Moderate | 1 | [
[
[
955,
24,
458
]
],
[
[
955,
24,
112
],
[
112,
1,
458
]
],
[
[
955,
6,
8374
],
[
8374,
45,
458
]
],
[
[
955,
21,
29273
],
[
29273,
... | [
[
[
"Mycophenolate mofetil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
]
],
[
[
"Mycophenolate mofetil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metro... | Mycophenolate mofetil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole (Compound) resembles Tinidazole (Compound)
Mycophenolate mofetil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tinidazole (Compound)
Mycophenolate mofetil (Compound) cause... |
DB00609 | DB06772 | 595 | 310 | [
"DDInter694",
"DDInter259"
] | Ethionamide | Cabazitaxel | A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
595,
24,
310
]
],
[
[
595,
24,
973
],
[
973,
24,
310
]
],
[
[
595,
21,
28810
],
[
28810,
60,
310
]
],
[
[
595,
63,
1451
],
[
1451,
... | [
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[... | Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Ethionamide (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is c... |
DB00443 | DB00880 | 251 | 359 | [
"DDInter195",
"DDInter360"
] | Betamethasone | Chlorothiazide | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Moderate | 1 | [
[
[
251,
24,
359
]
],
[
[
251,
24,
1577
],
[
1577,
1,
359
]
],
[
[
251,
21,
28784
],
[
28784,
60,
359
]
],
[
[
251,
24,
126
],
[
126,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroflumethiazid... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Betamethasone (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Chlorothiazide (Compound)
... |
DB00424 | DB00782 | 19 | 1,123 | [
"DDInter896",
"DDInter1535"
] | Hyoscyamine | Propantheline | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
19,
24,
1123
]
],
[
[
19,
5,
11646
],
[
11646,
44,
1123
]
],
[
[
19,
6,
7992
],
[
7992,
45,
1123
]
],
[
[
19,
21,
28898
],
[
28898,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Hyoscyamine",
"{u} (Compound) treats {v} (Disease)",
"pancreatitis"
],
[
"pancreatitis",
"{u} (Disease) is t... | Hyoscyamine (Compound) treats pancreatitis (Disease) and pancreatitis (Disease) is treated by Propantheline (Compound)
Hyoscyamine (Compound) binds CHRM1 (Gene) and CHRM1 (Gene) is bound by Propantheline (Compound)
Hyoscyamine (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Prop... |
DB00468 | DB00502 | 1,424 | 1,300 | [
"DDInter1557",
"DDInter853"
] | Quinine | Haloperidol | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the do... | Major | 2 | [
[
[
1424,
25,
1300
]
],
[
[
1424,
64,
78
],
[
78,
1,
1300
]
],
[
[
1424,
25,
543
],
[
543,
63,
1300
]
],
[
[
1424,
6,
6017
],
[
6017,
... | [
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Haloperidol"
]
],
[
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Droperidol"
],
[
"Droperidol",
"{u} (Compo... | Quinine may lead to a major life threatening interaction when taken with Droperidol and Droperidol (Compound) resembles Haloperidol (Compound)
Quinine may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00405 | DB00652 | 128 | 234 | [
"DDInter517",
"DDInter1421"
] | Dexbrompheniramine | Pentazocine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Moderate | 1 | [
[
[
128,
24,
234
]
],
[
[
128,
24,
1359
],
[
1359,
40,
234
]
],
[
[
128,
24,
537
],
[
537,
63,
234
]
],
[
[
128,
63,
999
],
[
999,
2... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Dezocine and Dezocine (Compound) resembles Pentazocine (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction... |
DB00013 | DB11793 | 1,255 | 738 | [
"DDInter1905",
"DDInter1297"
] | Urokinase | Niraparib | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1255,
24,
738
]
],
[
[
1255,
25,
1213
],
[
1213,
24,
738
]
],
[
[
1255,
64,
1578
],
[
1578,
24,
738
]
],
[
[
1255,
24,
848
],
[
848,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
... | Urokinase may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Urokinase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction... |
DB00762 | DB09104 | 613 | 286 | [
"DDInter973",
"DDInter1118"
] | Irinotecan | Magnesium hydroxide | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
613,
24,
286
]
],
[
[
613,
63,
752
],
[
752,
23,
286
]
],
[
[
613,
24,
1326
],
[
1326,
24,
286
]
],
[
[
613,
25,
859
],
[
859,
2... | [
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],... | Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide ... |
DB00559 | DB12001 | 152 | 564 | [
"DDInter223",
"DDInter7"
] | Bosentan | Abemaciclib | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Moderate | 1 | [
[
[
152,
24,
564
]
],
[
[
152,
24,
868
],
[
868,
24,
564
]
],
[
[
152,
63,
600
],
[
600,
24,
564
]
],
[
[
152,
25,
1017
],
[
1017,
6... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abemaciclib"
]
],
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
],
[
... | Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Flucon... |
DB00620 | DB11071 | 175 | 1,004 | [
"DDInter1855",
"DDInter1449"
] | Triamcinolone | Phenyl salicylate | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in ). Phenyl salicylate ma... | Moderate | 1 | [
[
[
175,
24,
1004
]
],
[
[
175,
23,
771
],
[
771,
62,
1004
]
],
[
[
175,
24,
1411
],
[
1411,
24,
1004
]
],
[
[
175,
40,
1573
],
[
1573,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Triamcinolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
... | Triamcinolone may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Phenyl salicylate
Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Tolbut... |
DB00574 | DB00844 | 121 | 314 | [
"DDInter717",
"DDInter1257"
] | Fenfluramine | Nalbuphine | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Moderate | 1 | [
[
[
121,
24,
314
]
],
[
[
121,
63,
828
],
[
828,
40,
314
]
],
[
[
121,
23,
173
],
[
173,
63,
314
]
],
[
[
121,
63,
421
],
[
421,
1,
... | [
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
]
],
[
[
"Fenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[... | Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Nalbuphine (Compound)
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Naloxone and Naloxone may cause a moderate interaction that could exa... |
DB00444 | DB01097 | 63 | 1,377 | [
"DDInter1765",
"DDInter1033"
] | Teniposide | Leflunomide | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
63,
25,
1377
]
],
[
[
63,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
63,
21,
29062
],
[
29062,
60,
1377
]
],
[
[
63,
63,
1461
],
[
1461,
... | [
[
[
"Teniposide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Teniposide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Leflun... | Teniposide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Teniposide (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Leflunomide (Compound)
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and... |
DB00022 | DB00065 | 268 | 581 | [
"DDInter1408",
"DDInter923"
] | Peginterferon alfa-2b | Infliximab | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions . Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory... | Moderate | 1 | [
[
[
268,
24,
581
]
],
[
[
268,
24,
1328
],
[
1328,
63,
581
]
],
[
[
268,
25,
1477
],
[
1477,
63,
581
]
],
[
[
268,
24,
912
],
[
912,
... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aurot... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Aurothioglucose and Aurothioglucose may cause a moderate interaction that could exacerbate diseases when taken with Infliximab
Peginterferon alfa-2b may lead to a major life threatening interaction when taken with Telb... |
DB00656 | DB00748 | 827 | 662 | [
"DDInter1851",
"DDInter297"
] | Trazodone | Carbinoxamine | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
827,
24,
662
]
],
[
[
827,
24,
28
],
[
28,
40,
662
]
],
[
[
827,
63,
1594
],
[
1594,
24,
662
]
],
[
[
827,
6,
8374
],
[
8374,
45... | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
... | Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl (Compound) resembles Carbinoxamine (Compound)
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could ... |
DB00222 | DB11827 | 245 | 433 | [
"DDInter825",
"DDInter669"
] | Glimepiride | Ertugliflozin | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
245,
24,
433
]
],
[
[
245,
23,
1103
],
[
1103,
23,
433
]
],
[
[
245,
25,
646
],
[
646,
24,
433
]
],
[
[
245,
24,
1020
],
[
1020,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[... | Glimepiride may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Ertugliflozin
Glimepiride may lead to a major life threatening interaction when taken with Cinoxacin and Cinoxacin may cause a... |
DB00712 | DB01193 | 1,274 | 819 | [
"DDInter763",
"DDInter12"
] | Flurbiprofen | Acebutolol | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Moderate | 1 | [
[
[
1274,
24,
819
]
],
[
[
1274,
24,
887
],
[
887,
1,
819
]
],
[
[
1274,
63,
1121
],
[
1121,
1,
819
]
],
[
[
1274,
21,
29005
],
[
29005,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
],
[
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Pindolol and Pindolol (Compound) resembles Acebutolol (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Bisoprolol and Bisoprolol (Compound) resembles Acebutolol (Compound)
... |
DB00593 | DB06691 | 1,464 | 849 | [
"DDInter695",
"DDInter1155"
] | Ethosuximide | Mepyramine | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
1464,
24,
849
]
],
[
[
1464,
63,
1594
],
[
1594,
24,
849
]
],
[
[
1464,
24,
272
],
[
272,
24,
849
]
],
[
[
1464,
24,
407
],
[
407,
... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine ... |
DB00851 | DB08908 | 611 | 713 | [
"DDInter463",
"DDInter564"
] | Dacarbazine | Dimethyl fumarate | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
611,
24,
713
]
],
[
[
611,
24,
996
],
[
996,
24,
713
]
],
[
[
611,
63,
552
],
[
552,
24,
713
]
],
[
[
611,
24,
270
],
[
270,
63,... | [
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bedaquiline"
]... | Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Carmustine... |
DB00544 | DB00808 | 970 | 1,605 | [
"DDInter757",
"DDInter916"
] | Fluorouracil | Indapamide | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Moderate | 1 | [
[
[
970,
24,
1605
]
],
[
[
970,
63,
811
],
[
811,
1,
1605
]
],
[
[
970,
21,
29135
],
[
29135,
60,
1605
]
],
[
[
970,
25,
126
],
[
126,
... | [
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
... | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Fluorouracil (Compound) causes Blister (Side Effect) and Blister (Side Effect) is caused by Indapamide (Compound)
Fluorouracil may lead to a major life threat... |
DB00438 | DB01024 | 149 | 1,096 | [
"DDInter330",
"DDInter1252"
] | Ceftazidime | Mycophenolic acid | Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibiotics, including cephalosporins, are PBP inhibitors that, through inhibition of esse... | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Moderate | 1 | [
[
[
149,
24,
1096
]
],
[
[
149,
21,
28666
],
[
28666,
60,
1096
]
],
[
[
149,
24,
387
],
[
387,
23,
1096
]
],
[
[
149,
40,
1124
],
[
1124,
... | [
[
[
"Ceftazidime",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Ceftazidime",
"{u} (Compound) causes {v} (Side Effect)",
"Nervous system disorder"
],
[
"Nervous system disord... | Ceftazidime (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Mycophenolic acid (Compound)
Ceftazidime may cause a moderate interaction that could exacerbate diseases when taken with Acyclovir and Acyclovir may cause a minor interaction that can limit clinica... |
DB00222 | DB01367 | 245 | 1,163 | [
"DDInter825",
"DDInter1572"
] | Glimepiride | Rasagiline | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Moderate | 1 | [
[
[
245,
24,
1163
]
],
[
[
245,
21,
28714
],
[
28714,
60,
1163
]
],
[
[
245,
24,
401
],
[
401,
24,
1163
]
],
[
[
245,
63,
176
],
[
176,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rasagiline"
]
],
[
[
"Glimepiride",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caus... | Glimepiride (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Rasagiline (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Ras... |
DB00489 | DB01050 | 17 | 848 | [
"DDInter1704",
"DDInter900"
] | Sotalol | Ibuprofen | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Moderate | 1 | [
[
[
17,
35,
848
]
],
[
[
17,
1,
1248
],
[
1248,
1,
848
]
],
[
[
17,
24,
1053
],
[
1053,
1,
848
]
],
[
[
17,
21,
28841
],
[
28841,
60... | [
[
[
"Sotalol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Sotalol",
"{u} (Compound) resembles {v} (Compound)",
"Atenolol"
],
[
"Atenolol... | Sotalol (Compound) resembles Ibuprofen (Compound) and
Sotalol (Compound) resembles Atenolol (Compound) and Atenolol (Compound) resembles Ibuprofen (Compound)
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound)
So... |
DB00163 | DB06810 | 1,461 | 397 | [
"DDInter1943",
"DDInter1484"
] | Vitamin E | Plicamycin | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Moderate | 1 | [
[
[
1461,
24,
397
]
],
[
[
1461,
24,
885
],
[
885,
24,
397
]
],
[
[
1461,
62,
1184
],
[
1184,
24,
397
]
],
[
[
1461,
23,
259
],
[
259,
... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plicamycin"
]
],
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
... | Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin
Vitamin E may cause a minor interaction that can limit clinical effects when taken with Anakinra and Anakinra... |
DB00146 | DB01070 | 160 | 1,098 | [
"DDInter265",
"DDInter558"
] | Calcifediol | Dihydrotachysterol | The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. | A vitamin D that can be regarded as a reduction product of vitamin D2. | Major | 2 | [
[
[
160,
25,
1098
]
],
[
[
160,
40,
1113
],
[
1113,
1,
1098
]
],
[
[
160,
40,
11418
],
[
11418,
40,
1098
]
],
[
[
160,
36,
386
],
[
386,
... | [
[
[
"Calcifediol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dihydrotachysterol"
]
],
[
[
"Calcifediol",
"{u} (Compound) resembles {v} (Compound)",
"Calcitriol"
],
[
"Calcitriol",
"{u} (Compound) resembles {v}... | Calcifediol (Compound) resembles Calcitriol (Compound) and Calcitriol (Compound) resembles Dihydrotachysterol (Compound)
Calcifediol (Compound) resembles Alfacalcidol (Compound) and Alfacalcidol (Compound) resembles Dihydrotachysterol (Compound)
Calcifediol (Compound) resembles Cholecalciferol (Compound) and Calcifedio... |
DB00285 | DB08896 | 1,100 | 292 | [
"DDInter1927",
"DDInter1576"
] | Venlafaxine | Regorafenib | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
1100,
24,
292
]
],
[
[
1100,
24,
79
],
[
79,
1,
292
]
],
[
[
1100,
6,
6017
],
[
6017,
45,
292
]
],
[
[
1100,
21,
28890
],
[
28890,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib (Compound) resembles Regorafenib (Compound)
Venlafaxine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Venlafaxine (Compound) causes Myocardial infarction (Side Effect... |
DB01193 | DB09080 | 819 | 144 | [
"DDInter12",
"DDInter1331"
] | Acebutolol | Olodaterol | A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
819,
24,
144
]
],
[
[
819,
25,
1011
],
[
1011,
24,
144
]
],
[
[
819,
63,
1445
],
[
1445,
24,
144
]
],
[
[
819,
24,
1154
],
[
1154,
... | [
[
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Acebutolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod... | Acebutolol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine ... |
DB00792 | DB01618 | 832 | 776 | [
"DDInter1878",
"DDInter1239"
] | Tripelennamine | Molindone | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Moderate | 1 | [
[
[
832,
24,
776
]
],
[
[
832,
24,
100
],
[
100,
24,
776
]
],
[
[
832,
63,
1442
],
[
1442,
24,
776
]
],
[
[
832,
35,
272
],
[
272,
2... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Molindone
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Scop... |
DB00759 | DB01024 | 1,620 | 1,096 | [
"DDInter1783",
"DDInter1252"
] | Tetracycline | Mycophenolic acid | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Moderate | 1 | [
[
[
1620,
24,
1096
]
],
[
[
1620,
63,
955
],
[
955,
1,
1096
]
],
[
[
1620,
24,
1193
],
[
1193,
62,
1096
]
],
[
[
1620,
63,
1031
],
[
1031,... | [
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
]
],
[
[
"Tetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolate mo... | Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolate mofetil and Mycophenolate mofetil (Compound) resembles Mycophenolic acid (Compound)
Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate ma... |
DB00002 | DB00526 | 1,284 | 1,555 | [
"DDInter344",
"DDInter1355"
] | Cetuximab | Oxaliplatin | Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
1284,
24,
1555
]
],
[
[
1284,
24,
384
],
[
384,
63,
1555
]
],
[
[
1284,
24,
589
],
[
589,
24,
1555
]
],
[
[
1284,
25,
770
],
[
770,
... | [
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
... | Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplati... |
DB01033 | DB15965 | 328 | 1,330 | [
"DDInter1156",
"DDInter1270"
] | Mercaptopurine | Naxitamab | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
328,
24,
1330
]
],
[
[
328,
24,
1532
],
[
1532,
24,
1330
]
],
[
[
328,
63,
597
],
[
597,
24,
1330
]
],
[
[
328,
25,
770
],
[
770,
... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenico... |
DB00853 | DB06372 | 1,686 | 259 | [
"DDInter1762",
"DDInter1594"
] | Temozolomide | Rilonacept | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold au... | Moderate | 1 | [
[
[
1686,
24,
259
]
],
[
[
1686,
63,
1461
],
[
1461,
23,
259
]
],
[
[
1686,
24,
37
],
[
37,
24,
259
]
],
[
[
1686,
24,
1330
],
[
1330,
... | [
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[... | Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Rilonacept
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomusti... |
DB00700 | DB06715 | 312 | 239 | [
"DDInter656",
"DDInter1500"
] | Eplerenone | Potassium Iodide | Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone c... | Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyr... | Major | 2 | [
[
[
312,
25,
239
]
],
[
[
312,
21,
28883
],
[
28883,
60,
239
]
],
[
[
312,
24,
1274
],
[
1274,
24,
239
]
],
[
[
312,
63,
1512
],
[
1512,
... | [
[
[
"Eplerenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium Iodide"
]
],
[
[
"Eplerenone",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (Side Effect) is cause... | Eplerenone (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Potassium Iodide (Compound)
Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when ... |
DB00701 | DB00762 | 1,091 | 613 | [
"DDInter90",
"DDInter973"
] | Amprenavir | Irinotecan | Amprenavir is a protease inhibitor used to treat HIV infection. | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Major | 2 | [
[
[
1091,
25,
613
]
],
[
[
1091,
6,
10417
],
[
10417,
45,
613
]
],
[
[
1091,
21,
28658
],
[
28658,
60,
613
]
],
[
[
1091,
24,
292
],
[
292... | [
[
[
"Amprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Irinotecan"
]
],
[
[
"Amprenavir",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",
"Irinoteca... | Amprenavir (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Irinotecan (Compound)
Amprenavir (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Irinotecan (Compound)
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib and Regoraf... |
DB01064 | DB01177 | 1,148 | 77 | [
"DDInter987",
"DDInter904"
] | Isoprenaline | Idarubicin | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
1148,
24,
77
]
],
[
[
1148,
7,
2969
],
[
2969,
46,
77
]
],
[
[
1148,
7,
5178
],
[
5178,
57,
77
]
],
[
[
1148,
18,
2183
],
[
2183,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Isoprenaline",
"{u} (Compound) upregulates {v} (Gene)",
"CDKN1A"
],
[
"CDKN1A",
"{u} (Gene) is upregulated by ... | Isoprenaline (Compound) upregulates CDKN1A (Gene) and CDKN1A (Gene) is upregulated by Idarubicin (Compound)
Isoprenaline (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is downregulated by Idarubicin (Compound)
Isoprenaline (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Idarubicin (Compou... |
DB00480 | DB00682 | 1,668 | 126 | [
"DDInter1035",
"DDInter1951"
] | Lenalidomide | Warfarin | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenali... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Minor | 0 | [
[
[
1668,
23,
126
]
],
[
[
1668,
25,
671
],
[
671,
62,
126
]
],
[
[
1668,
64,
681
],
[
681,
23,
126
]
],
[
[
1668,
24,
663
],
[
663,
... | [
[
[
"Lenalidomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvastatin"
],
[
"Fluvastat... | Lenalidomide may lead to a major life threatening interaction when taken with Fluvastatin and Fluvastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin
Lenalidomide may lead to a major life threatening interaction when taken with Pravastatin and Pravastatin may cause a minor int... |
DB03619 | DB08901 | 557 | 1,468 | [
"DDInter501",
"DDInter1492"
] | Deoxycholic acid | Ponatinib | Deoxycholic acid is a a bile acid which emulsifies and solubilizes dietary fats in the intestine, and when injected subcutaneously, it disrupts cell membranes in adipocytes and destroys fat cells in that tissue. In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
557,
24,
1468
]
],
[
[
557,
24,
1598
],
[
1598,
63,
1468
]
],
[
[
557,
24,
330
],
[
330,
25,
1468
]
],
[
[
557,
63,
553
],
[
553,
... | [
[
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Deoxycholic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
... | Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Deoxycholic acid may cause a moderate interaction that could exacerbate diseases when taken with Ramuci... |
DB00938 | DB01222 | 455 | 617 | [
"DDInter1635",
"DDInter246"
] | Salmeterol | Budesonide | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Minor | 0 | [
[
[
455,
23,
617
]
],
[
[
455,
62,
1351
],
[
1351,
1,
617
]
],
[
[
455,
23,
1220
],
[
1220,
1,
617
]
],
[
[
455,
5,
11649
],
[
11649,
... | [
[
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Budesonide"
]
],
[
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Flunisolide"
],
[
... | Salmeterol may cause a minor interaction that can limit clinical effects when taken with Flunisolide and Flunisolide (Compound) resembles Budesonide (Compound)
Salmeterol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (Compou... |
DB00552 | DB00851 | 1,238 | 611 | [
"DDInter1425",
"DDInter463"
] | Pentostatin | Dacarbazine | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Moderate | 1 | [
[
[
1238,
24,
611
]
],
[
[
1238,
5,
11555
],
[
11555,
44,
611
]
],
[
[
1238,
23,
739
],
[
739,
62,
611
]
],
[
[
1238,
23,
646
],
[
646,
... | [
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacarbazine"
]
],
[
[
"Pentostatin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Dis... | Pentostatin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Dacarbazine (Compound)
Pentostatin may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin and Lomefloxacin may cause a minor interaction that can limit clinical effects when take... |
DB09312 | DB11817 | 967 | 1,259 | [
"DDInter106",
"DDInter165"
] | Antithymocyte immunoglobulin (rabbit) | Baricitinib | Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin i... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
967,
25,
1259
]
],
[
[
967,
23,
1193
],
[
1193,
23,
1259
]
],
[
[
967,
24,
949
],
[
949,
24,
1259
]
],
[
[
967,
24,
1129
],
[
1129,
... | [
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Antilymphocyte immunoglobulin (horse)",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v... | Antilymphocyte immunoglobulin (horse) may lead to a major life threatening interaction when taken with Baricitinib
Antilymphocyte immunoglobulin (horse) may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical e... |
DB01165 | DB01229 | 1,539 | 973 | [
"DDInter1325",
"DDInter1377"
] | Ofloxacin | Paclitaxel | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intr... | Minor | 0 | [
[
[
1539,
23,
973
]
],
[
[
1539,
6,
5912
],
[
5912,
45,
973
]
],
[
[
1539,
6,
3199
],
[
3199,
57,
973
]
],
[
[
1539,
21,
30098
],
[
30098,... | [
[
[
"Ofloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Paclitaxel"
]
],
[
[
"Ofloxacin",
"{u} (Compound) binds {v} (Gene)",
"ABCC2"
],
[
"ABCC2",
"{u} (Gene) is bound by {v} (Compound)",
... | Ofloxacin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Paclitaxel (Compound)
Ofloxacin (Compound) binds TOP2A (Gene) and TOP2A (Gene) is downregulated by Paclitaxel (Compound)
Ofloxacin (Compound) causes Swelling face (Side Effect) and Swelling face (Side Effect) is caused by Paclitaxel (Compound)
Ofloxac... |
DB01005 | DB01042 | 995 | 1,307 | [
"DDInter894",
"DDInter1144"
] | Hydroxyurea | Melphalan | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-con... | Moderate | 1 | [
[
[
995,
24,
1307
]
],
[
[
995,
5,
11555
],
[
11555,
44,
1307
]
],
[
[
995,
21,
28745
],
[
28745,
60,
1307
]
],
[
[
995,
23,
956
],
[
956,... | [
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Melphalan"
]
],
[
[
"Hydroxyurea",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disea... | Hydroxyurea (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Melphalan (Compound)
Hydroxyurea (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Melphalan (Compound)
Hydroxyurea may cause a minor interaction that can li... |
DB11730 | DB12141 | 351 | 971 | [
"DDInter1588",
"DDInter817"
] | Ribociclib | Gilteritinib | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Major | 2 | [
[
[
351,
25,
971
]
],
[
[
351,
64,
1135
],
[
1135,
23,
971
]
],
[
[
351,
62,
1247
],
[
1247,
23,
971
]
],
[
[
351,
23,
466
],
[
466,
... | [
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Ribociclib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole ma... |
DB00467 | DB09407 | 1,467 | 853 | [
"DDInter644",
"DDInter1114"
] | Enoxacin | Magnesium chloride | A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid. | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Moderate | 1 | [
[
[
1467,
24,
853
]
],
[
[
1467,
1,
1539
],
[
1539,
24,
853
]
],
[
[
1467,
24,
544
],
[
544,
24,
853
]
],
[
[
1467,
24,
460
],
[
460,
... | [
[
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium chloride"
]
],
[
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a moder... | Enoxacin (Compound) resembles Ofloxacin (Compound) and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium chloride
Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate intera... |
DB05316 | DB08871 | 749 | 36 | [
"DDInter1467",
"DDInter666"
] | Pimavanserin | Eribulin | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
749,
24,
36
]
],
[
[
749,
63,
1424
],
[
1424,
24,
36
]
],
[
[
749,
64,
609
],
[
609,
24,
36
]
],
[
[
749,
24,
28
],
[
28,
63,
... | [
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
... | Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Pimavanserin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may ca... |
DB00804 | DB09128 | 1,507 | 1,241 | [
"DDInter543",
"DDInter231"
] | Dicyclomine | Brexpiprazole | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different b... | Moderate | 1 | [
[
[
1507,
24,
1241
]
],
[
[
1507,
24,
407
],
[
407,
63,
1241
]
],
[
[
1507,
24,
543
],
[
543,
24,
1241
]
],
[
[
1507,
63,
832
],
[
832,
... | [
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
]
],
[
[
"Dicyclomine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
... | Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole
Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide ... |
DB00586 | DB00834 | 1,512 | 932 | [
"DDInter537",
"DDInter1215"
] | Diclofenac | Mifepristone | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Moderate | 1 | [
[
[
1512,
24,
932
]
],
[
[
1512,
6,
10417
],
[
10417,
45,
932
]
],
[
[
1512,
21,
31403
],
[
31403,
60,
932
]
],
[
[
1512,
24,
848
],
[
848... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Diclofenac",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",... | Diclofenac (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Mifepristone (Compound)
Diclofenac (Compound) causes Toxic shock syndrome (Side Effect) and Toxic shock syndrome (Side Effect) is caused by Mifepristone (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00176 | DB08875 | 529 | 1,618 | [
"DDInter770",
"DDInter262"
] | Fluvoxamine | Cabozantinib | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
529,
24,
1618
]
],
[
[
529,
23,
1135
],
[
1135,
62,
1618
]
],
[
[
529,
24,
723
],
[
723,
24,
1618
]
],
[
[
529,
24,
1662
],
[
1662,
... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Fluvoxamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Fluvoxamine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepita... |
DB00912 | DB11228 | 473 | 721 | [
"DDInter1581",
"DDInter1184"
] | Repaglinide | Methylcellulose | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Methyl cellulose polymer consisting of numerous linked glucose molecules used as a stabiliser, thickener and emulsifier for foodstuffs and cosmetics. The Degree of Substitution (DS) of a given form of methyl cellulose is defined as the average number of substituted hydroxyl groups per glucose with a theoretical maximum... | Minor | 0 | [
[
[
473,
23,
721
]
],
[
[
473,
24,
824
],
[
824,
24,
1411
],
[
1411,
23,
721
]
],
[
[
473,
5,
11640
],
[
11640,
44,
1411
],
[
1411,
23,
... | [
[
[
"Repaglinide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylcellulose"
]
],
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Probenecid"
],
... | Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Probenecid and Probenecid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Methylcellulose
... |
DB00095 | DB15762 | 66 | 725 | [
"DDInter623",
"DDInter1644"
] | Efalizumab | Satralizumab | Humanized IgG1 kappa isotype monoclonal antibody that binds to human CD11a. Efalizumab has a molecular weight of approximately 150 kilodaltons and is produced in a Chinese hamster ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin. The FDA approved efalizumab in 2003. It wa... | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Moderate | 1 | [
[
[
66,
24,
725
]
],
[
[
66,
23,
1193
],
[
1193,
23,
725
]
],
[
[
66,
24,
1362
],
[
1362,
24,
725
]
],
[
[
66,
63,
58
],
[
58,
24,
... | [
[
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
]
],
[
[
"Efalizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
... | Efalizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Satralizumab
Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Ol... |
DB01064 | DB06262 | 1,148 | 1,354 | [
"DDInter987",
"DDInter606"
] | Isoprenaline | Droxidopa | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that ... | Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a def... | Moderate | 1 | [
[
[
1148,
24,
1354
]
],
[
[
1148,
63,
874
],
[
874,
24,
1354
]
],
[
[
1148,
24,
584
],
[
584,
40,
1354
]
],
[
[
1148,
35,
1191
],
[
1191,
... | [
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Droxidopa"
]
],
[
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
... | Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa
Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Levonordefrin an... |
DB00215 | DB01124 | 1,230 | 1,411 | [
"DDInter388",
"DDInter1828"
] | Citalopram | Tolbutamide | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1230,
24,
1411
]
],
[
[
1230,
24,
959
],
[
959,
40,
1411
]
],
[
[
1230,
6,
10215
],
[
10215,
45,
1411
]
],
[
[
1230,
21,
28746
],
[
28... | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Citalopram (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tolbutamide (Compound)
Citalopram (Compound) causes Erythema (Side Effect) and Erythema... |
DB06688 | DB11760 | 1,430 | 119 | [
"DDInter1677",
"DDInter1742"
] | Sipuleucel-T | Talazoparib | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
1430,
24,
119
]
],
[
[
1430,
63,
66
],
[
66,
24,
119
]
],
[
[
1430,
24,
713
],
[
713,
24,
119
]
],
[
[
1430,
24,
287
],
[
287,
6... | [
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Sipuleucel-T",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
... | Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarat... |
DB00108 | DB00322 | 1,066 | 141 | [
"DDInter1268",
"DDInter742"
] | Natalizumab | Floxuridine | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Major | 2 | [
[
[
1066,
25,
141
]
],
[
[
1066,
25,
1083
],
[
1083,
40,
141
]
],
[
[
1066,
25,
1064
],
[
1064,
25,
141
]
],
[
[
1066,
25,
611
],
[
611,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Floxuridine"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine"
],
[
"Trifluridine",
... | Natalizumab may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine (Compound) resembles Floxuridine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with F... |
DB06212 | DB12267 | 165 | 1,476 | [
"DDInter1833",
"DDInter233"
] | Tolvaptan | Brigatinib | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
165,
24,
1476
]
],
[
[
165,
23,
1135
],
[
1135,
23,
1476
]
],
[
[
165,
63,
629
],
[
629,
24,
1476
]
],
[
[
165,
24,
1456
],
[
1456,
... | [
[
[
"Tolvaptan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Tolvaptan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"... | Tolvaptan may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may c... |
DB00281 | DB11652 | 608 | 1,155 | [
"DDInter1066",
"DDInter1891"
] | Lidocaine | Tucatinib | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anest... | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer w... | Moderate | 1 | [
[
[
608,
24,
1155
]
],
[
[
608,
23,
1101
],
[
1101,
23,
1155
]
],
[
[
608,
24,
1419
],
[
1419,
24,
1155
]
],
[
[
608,
23,
1320
],
[
1320,
... | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"... | Lidocaine may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may ca... |
DB00377 | DB01601 | 1,494 | 833 | [
"DDInter1382",
"DDInter1089"
] | Palonosetron | Lopinavir | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Lopinavir is an antiretroviral protease inhibitor used in combination with other antiretrovirals in the treatment of HIV-1 infection. Lopinavir is marketed and administered exclusively in combination with [ritonavir] - this combination, first marketed by Abbott under the brand name Kaletra in 2000, is necessary due to ... | Moderate | 1 | [
[
[
1494,
24,
833
]
],
[
[
1494,
25,
1327
],
[
1327,
40,
833
]
],
[
[
1494,
6,
7950
],
[
7950,
45,
833
]
],
[
[
1494,
24,
144
],
[
144,
... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lopinavir"
]
],
[
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
],
[
"Saquina... | Palonosetron may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir (Compound) resembles Lopinavir (Compound)
Palonosetron (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Lopinavir (Compound)
Palonosetron may cause a moderate interaction that could exacerbate diseases wh... |
DB00581 | DB01246 | 355 | 820 | [
"DDInter1018",
"DDInter45"
] | Lactulose | Alimemazine | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
355,
24,
820
]
],
[
[
355,
24,
675
],
[
675,
25,
820
]
],
[
[
355,
63,
508
],
[
508,
1,
820
]
],
[
[
355,
24,
9
],
[
9,
1,
... | [
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene may lead to a major life threatening interaction when taken with Alimemazine
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazi... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.